Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic LeukemiaHERMAN, Sarah E. M; JOHNSON, Amy J.Clinical cancer research (Print). 2012, Vol 18, Num 15, pp 4013-4018, issn 1078-0432, 6 p.Article

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaHERMAN, Sarah E. M; LAPALOMBELLA, Rosa; BYRD, John C et al.Blood. 2011, Vol 117, Num 16, pp 4323-4327, issn 0006-4971, 5 p.Article

Phosphatidylinositol 3-kinase-8 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsHERMAN, Sarah E. M; GORDON, Amber L; GIESE, Neill A et al.Blood. 2010, Vol 116, Num 12, pp 2078-2088, issn 0006-4971, 11 p.Article

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityLANNUTTI, Brian J; MEADOWS, Sarah A; DRUKER, Brian J et al.Blood. 2011, Vol 117, Num 2, pp 591-594, issn 0006-4971, 4 p.Article

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolMAHONEY, Emilia; LUCAS, David M; BLUM, Kristie A et al.Blood. 2012, Vol 120, Num 6, pp 1262-1273, issn 0006-4971, 12 p.Article

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBO YU; YICHENG MAO; JARJOURA, David et al.Blood. 2013, Vol 121, Num 1, pp 136-147, issn 0006-4971, 12 p.Article

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765HERMAN, Sarah E. M; GORDON, Amber L; HAMDY, Ahmed et al.Blood. 2011, Vol 117, Num 23, pp 6287-6296, issn 0006-4971, 10 p.Article